{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:39:15Z","timestamp":1760852355791,"version":"3.35.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.ejphar.2008.08.011","type":"journal-article","created":{"date-parts":[[2008,8,25]],"date-time":"2008-08-25T08:02:21Z","timestamp":1219651341000},"page":"34-38","source":"Crossref","is-referenced-by-count":17,"title":["Apomorphine-induced emesis in dogs: Differential sensitivity to established and novel dopamine D2\/5-HT1A antipsychotic compounds"],"prefix":"10.1016","volume":"597","author":[{"given":"Ronan","family":"Depoort\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Barret-Gr\u00e9voz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2008.08.011_bib1","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties","volume":"31","author":"Bardin","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2008.08.011_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FBP.0b013e3280ae6c96","article-title":"Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2\/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics","volume":"18","author":"Bardin","year":"2007","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3565(25)26174-2","article-title":"Effect of ablation of the chemoreceptor trigger zone (CT zone) on the emetic response to intraventricular injection of apomorphine and emetine in the dog","volume":"134","author":"Bhargava","year":"1961","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.08.011_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00004850-199300830-00006","article-title":"A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder","volume":"8","author":"Boyer","year":"1993","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2008.08.011_bib5","first-page":"123","article-title":"Efficacy and safety of bifeprunox in the treatment of patients with acute exacerbations of schizophrenia: results of a dose-finding study","volume":"31","author":"Casey","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2008.08.011_bib6","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.npp.1300262","article-title":"SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. I: neurochemical and electrophysiological profile","volume":"28","author":"Claustre","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2008.08.011_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2006.01.051","article-title":"Partial agonism of the antipsychotics SSR181507, aripiprazole and bifeprunox at D2 receptors: G-protein activation and prolactin release","volume":"535","author":"Cosi","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib8","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1021\/jm030505a","article-title":"Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction","volume":"47","author":"Cowart","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2008.08.011_bib9","series-title":"Dopamine in the CNS II","first-page":"239","article-title":"Behavioural pharmacology of dopamine D2 and D3 receptors: use of the knock-out mice approach","author":"Depoort\u00e8re","year":"2002"},{"issue":"11","key":"10.1016\/j.ejphar.2008.08.011_bib44","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/sj.npp.1300261","article-title":"SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity","volume":"28","author":"Depoortere","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2008.08.011_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjp.0707159","article-title":"F15063, a compound with D2\/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia","volume":"151","author":"Depoort\u00e8re","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjp.0707160","article-title":"F15063, a compound with D2\/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: III) Profile in tests predictive of activity against cognitive deficits and negative symptoms of schizophrenia","volume":"151","author":"Depoort\u00e8re","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0014-2999(88)90789-3","article-title":"Antihypertensive effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in conscious dogs","volume":"147","author":"Di Francesco","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib13","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/S0960-894X(01)00425-5","article-title":"New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities","volume":"11","author":"Feenstra","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2008.08.011_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00004850-199300830-00005","article-title":"An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression","volume":"8","author":"Grof","year":"1993","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib15","article-title":"Pharmacological profile of RGH188, a novel dopamine D3\/D2 receptor antagonist\/partial agonist atypical antipsychotic","volume":"16 (Suppl.)","author":"Gyertyan","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0014-2999(87)90009-4","article-title":"Central mechanisms for apomorphine-induced emesis in the dog","volume":"144","author":"Harding","year":"1987","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib17","unstructured":"Invega : Scientific Discussion document, 2007; available from: http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/invega\/invega.htm."},{"key":"10.1016\/j.ejphar.2008.08.011_bib18","first-page":"462","article-title":"SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems","volume":"226","author":"Iorio","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2008.08.011_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib20","first-page":"46","article-title":"The dopamine D3 receptor: Chinese hamsters or Chinese whispers? Trends Pharmacol","volume":"15","author":"Large","year":"1994","journal-title":"Sci."},{"key":"10.1016\/j.ejphar.2008.08.011_bib21","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","article-title":"Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes","volume":"20","author":"Lawler","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2008.08.011_bib22","first-page":"758","article-title":"5-HT(1A) receptor dysfunction in female patients with schizophrenia.Biol","volume":"50","author":"Lee","year":"2001","journal-title":"Psychiatry"},{"key":"10.1016\/j.ejphar.2008.08.011_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0014-2999(94)90756-0","article-title":"Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin","volume":"253","author":"Lucot","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/1568007053544165","article-title":"Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke","volume":"4","author":"Lutsep","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.ejphar.2008.08.011_bib25","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/S0924-977X(02)80374-1","article-title":"SLV313: a novel antipsychotic with additional antidepressant and anxiolytic-like actions","volume":"12","author":"McCreary","year":"2002","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bcp.2004.05.019","article-title":"Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through G\u03b1(qo5)","volume":"68","author":"Moreland","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1254\/jphs.FPJ04035X","article-title":"Diphenidol has no actual broad antiemetic activity in dogs and ferrets","volume":"96","author":"Nakayama","year":"2004","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2008.08.011_bib28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.bjp.0707158","article-title":"F15063, a potential antipsychotic with D2\/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile","volume":"151","author":"Newman-Tancredi","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib29","first-page":"539","article-title":"Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics","volume":"8","author":"Newman-Tancredi","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2008.08.011_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/BF00428152","article-title":"Antiemetic specificity of dopamine antagonists","volume":"78","author":"Niemegeers","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2008.08.011_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1254\/jjp.64.109","article-title":"Antiemetic effects of serotonergic 5-HT1A-receptor agonists in Suncus murinus","volume":"64","author":"Okada","year":"1994","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.pbb.2005.03.012","article-title":"Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets","volume":"81","author":"Osinski","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2008.08.011_bib33","first-page":"122","article-title":"Efficacy and safety of bifeprunox versus placebo in the treatment of patients with acute exacerbations of schizophrenia","volume":"31","author":"Rapaport","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2008.08.011_bib34","unstructured":"Risperdal Consta\u2122 Product monograph, 2005."},{"key":"10.1016\/j.ejphar.2008.08.011_bib35","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0149-2918(03)80159-5","article-title":"Review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone","volume":"25","author":"Robinson","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2008.08.011_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00422105","article-title":"Antagonism of apomorphine-induced sterotypy and emesis in dogs by thioridazine, haloperidol, and pimozide","volume":"26","author":"Rotrosen","year":"1972","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.ejphar.2008.08.011_bib37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2885.1990.tb00763.x","article-title":"Apomorphine-induced emesis in the dog\u2014routes of administration, efficacy and synergism by naloxone","volume":"13","author":"Scherkl","year":"1990","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2008.08.011_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0016-5085(19)36357-7","article-title":"A new concept of organization of the central emetic mechanism: recent studies on the sites of action of apomorphine, copper sulfate and cardiac glycosides","volume":"22","author":"Wang","year":"1952","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2008.08.011_bib39","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1093\/ajhp\/60.23.2437","article-title":"Aripiprazole","volume":"60","author":"Winans","year":"2003","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejphar.2008.08.011_bib40","first-page":"72","article-title":"DU-127090 Solvay\/H Lundbeck","volume":"4","author":"Wolf","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2008.08.011_bib41","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0091-3057(94)90438-3","article-title":"Antiemetic effects of 5-HT1A agonists in the pigeon","volume":"49","author":"Wolff","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2008.08.011_bib42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0024-3205(95)02186-M","article-title":"A dopamine D3 receptor agonist, 7-OH-DPAT, causes vomiting in the dog","volume":"57","author":"Yoshida","year":"1995","journal-title":"Life Sci."},{"issue":"1\u20133","key":"10.1016\/j.ejphar.2008.08.011_bib45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0014-2999(96)00061-1","article-title":"Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret","volume":"301","author":"Yoshikawa","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.08.011_bib43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjp.0704078","article-title":"The broad spectrum anti-emetic activity of AS-8110, a novel dopamine D2, D3 and 5-HT3 receptors antagonist","volume":"133","author":"Yoshikawa","year":"2001","journal-title":"Br. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908008856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908008856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T17:22:39Z","timestamp":1738344159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299908008856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":45,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0014299908008856"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.08.011","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}